choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Tesaro IPO

Tesaro IPO Newsletter
  • Two antibody startups file for IPOs amid summer slump 23 Aug 2024 16:53 GMT

    … , the pace of biotech IPOs has slowed. Fifteen drugmakers … investor exits still exist in IPOs and pharmaceutical company acquisitions, … and healthcare. "The IPO landscape showed a mixed … was incorporated in 2019. Tesaro, which developed the PARP inhibitor …

  • Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates 12 Nov 2024 12:10 GMT

    … , the Company: Completed its upsized initial public offering, raising approximately $258.7 million … acquired by Servier) and at TESARO (acquired by GlaxoSmithKline). Mr. Held … million from the Company’s IPO, after deducting underwriting discounts and …

  • AnaptysBio raises $75 million in initial public offering 27 Jan 2017 02:21 GMT

    … $75 million Thursday in an initial public offering, making it the first U … for inflammatory drugs and with Tesaro for cancer therapies. Credit Suisse …

  • Bio Roundup: PARP Progress, A New Commish, IPO-Palooza & More 04 Oct 2019 11:35 GMT

    Xconomy National —  It’s been a strange up and down ride for PARP inhibitors, a relatively new class of cancer drugs. Named for the tumor protein they target, PARPs rebounded after a big clinical setback in 2011 and have been at the center of many buyouts …

  • Bio Roundup: Opioid Exposé, Gilead’s Gambit, Life Science IPOs & More 19 Jul 2019 14:21 GMT

    Xconomy National —  The opioid crisis reaches all corners of the nation, and newly released data this week revealed how the growth of the epidemic tracked with a massive increase in the production and distribution of these drugs. From 2006 to 2012, the …

  • IPO Update: Ideaya Biosciences Readies Terms For IPO 15 May 2019 17:45 GMT

    … : Immunocore AstraZeneca (AZN) Clovis (CLVS) Tesaro (GSK) Pfizer (PFE) Agios (AGIO … Seeking Alpha Marketplace research service IPO Edge includes my full commentary … and opinion on the IPO. Members of IPO Edge get the latest …

  • IDEAYA Biosciences Files For U.S. IPO 03 May 2019 21:00 GMT

    … Immunocore AstraZeneca (AZN) Clovis (CLVS) Tesaro (GSK) Pfizer (PFE) Agios ( … Citigroup, and Jefferies. Expected IPO Pricing Date: To be announced … Alpha Marketplace research service IPO Edge includes my full … opinion on the IPO. Members of IPO Edge get the …

  • Preclinical IPOs: Is the window starting to close? 05 Jan 2019 11:05 GMT

    … almost $800million through their IPOs, despite none having permission … this year, such as Tesaro by GlaxoSmithKline and Juno … [5] Solid Biosciences’ IPO Hits Potential Snag. Published … [6] Solid Biosciences Completes IPO. Published January 26. Available …

  • Tesaro: Quick Goodbye 03 Dec 2018 23:29 GMT

    … the way. While investors in Tesaro have finally received some sort … reached a deal to acquire Tesaro for $75 per share in … of the losses incurred by Tesaro, and now thus GSK. What … research on all the latest IPOs, M&A activity and …

  • GlaxoSmithKline Strikes $5B M&A Deal With Tesaro In Quest To Boost Oncology Franchise 03 Dec 2018 15:54 GMT

    … plc (NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced … Important The acquisition of Tesaro brings to GlaxoSmithKline a … mutation or biomarker status. Tesaro is also working on … Dates, Clinical Trials And IPOs Attention Biotech Investors: Mark Your …

Satisfied with the content?

Continue to create your account.